TD Cowen analyst Charles Rhyee initiated coverage of Option Care Health (OPCH) with a Hold rating and $30 price target Option is the leading home and alternate site infusion provider with exposure to specialty and a balance sheet that supports capital deployment, the analyst tells investors in a research note. The firm thinks the company can hit its long-term growth targets, but says this is already reflected in consensus estimates. TD cites this and a lack of obvious share catalysts for the Hold rating.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health Amends Credit Agreement for Refinancing
- Option Care Health: Strategic Positioning and Growth Potential Drive Buy Rating
- Option Care Health up 5% at $29 per share following positive Barron’s note
- Option Care Health shares ‘undervalued’, says Barron’s
- Option Care Health Appoints New CFO Meenal Sethna